[go: up one dir, main page]

WO2022240165A1 - Composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire liée à l'âge - Google Patents

Composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire liée à l'âge Download PDF

Info

Publication number
WO2022240165A1
WO2022240165A1 PCT/KR2022/006706 KR2022006706W WO2022240165A1 WO 2022240165 A1 WO2022240165 A1 WO 2022240165A1 KR 2022006706 W KR2022006706 W KR 2022006706W WO 2022240165 A1 WO2022240165 A1 WO 2022240165A1
Authority
WO
WIPO (PCT)
Prior art keywords
macular degeneration
age
related macular
formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/006706
Other languages
English (en)
Korean (ko)
Inventor
이준원
변석호
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Publication of WO2022240165A1 publication Critical patent/WO2022240165A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration.
  • Age-related macular degeneration is a disease caused by various changes in the macular area of the retina with aging. The incidence increases with age, and it is known that there are about 200 million patients worldwide as the number one cause of adult blindness in developed countries. Therefore, as the elderly population increases in Korea, the incidence is expected to increase further.
  • the macula refers to the central part of the nerve tissue called the retina, and is responsible for central vision because photoreceptor cells that respond to light stimulation are concentrated.
  • Age-related macular degeneration is a loss of these macular photoreceptor cells as aging progresses and causes visual impairment, and can be divided into 1 wet or exudative form and 2 dry or non-exudative form.
  • neovascular, exudative form when choroidal neovascularization grows under the retina, it is treated by intraocular injection of anti-vascular endothelial growth factor (VEGF) monoclonal antibody.
  • VEGF anti-vascular endothelial growth factor
  • the dry (atrophic) form accounts for most of AMD and refers to cases in which lesions such as drusen, pigmentary abnormalities, or atrophy of the retinal epithelium occur in the retina. Progressive macular degeneration during dryness is called geographic atrophy (GA), and currently there is no treatment, which is the biggest challenge in age-related macular degeneration.
  • GA geographic atrophy
  • the present invention was conceived to solve the above problems, and the present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration.
  • the pharmaceutical composition of the present invention is expected to be widely used in the medical field because it exhibited a very remarkable therapeutic effect not only in wet but also in dry age-related macular degeneration for which there is no treatment.
  • An object of the present invention is to provide a pharmaceutical composition for preventing or treating age-related macular degeneration.
  • ASD Age-related macular degeneration
  • AMD is a disease caused by various changes in the macular region of the retina with aging.
  • the incidence increases with age, and it is known that there are about 200 million patients worldwide as the number one cause of adult blindness in developed countries. Therefore, as the elderly population increases in Korea, the incidence is expected to increase further.
  • the macula refers to the central part of the nerve tissue called the retina, and is responsible for central vision because photoreceptor cells that respond to light stimulation are concentrated.
  • Age-related macular degeneration is a loss of these macular photoreceptor cells as aging progresses and causes visual impairment, and can be divided into 1 wet or exudative form and 2 dry or non-exudative form.
  • neovascular, exudative form when choroidal neovascularization grows under the retina, it is treated by intraocular injection of anti-vascular endothelial growth factor (VEGF) monoclonal antibody.
  • VEGF anti-vascular endothelial growth factor
  • the dry (atrophic) form accounts for most of AMD and refers to cases in which lesions such as drusen, pigmentary abnormalities, or atrophy of the retinal epithelium occur in the retina. Progressive macular degeneration during dryness is called geographic atrophy (GA), and currently there is no treatment, which is the biggest challenge in age-related macular degeneration.
  • GA geographic atrophy
  • nicotinamide is a kind of vitamin B complex, which coexists with nicotinic acid in plants and is widely distributed, and exists as a component of NAD + or NADP +, which is a redox coenzyme, in vivo . Also referred to as niacin in a narrow sense.
  • Nicotinamide also known as niacinamide, is a form of vitamin B3 found in foods and used as a dietary supplement and drug. As a supplement, it is also used orally to prevent and treat pellagra (a disease caused by niacin deficiency).
  • the nicotinamide is represented by Formula 1 below.
  • “derivative of nicotinamide” means a compound obtained by changing a part of the molecular structure of nicotinamide represented by Formula 1 above.
  • the nicotinamide derivative is represented by Formula 2 or Formula 3 below, but is not limited thereto.
  • pharmaceutical composition means a composition administered for a specific purpose.
  • the pharmaceutical composition of the present invention is to prevent or treat age-related macular degeneration, and may include a compound involved in this and a pharmaceutically acceptable carrier, excipient or diluent.
  • the pharmaceutical composition according to the present invention contains 0.1 to 50% by weight of the active ingredient of the present invention based on the total weight of the composition.
  • Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • the pharmaceutical composition for the prevention and treatment of age-related macular degeneration of the present invention is preferably any one compound selected from Formulas 1 to 3, or pharmaceutically acceptable salts, optical isomers, hydrates and solvates thereof. It includes a compound selected from.
  • the pharmaceutically acceptable salt should have low toxicity to the human body and should not adversely affect the biological activity and physicochemical properties of the parent compound.
  • a pharmaceutically acceptable salt may be an acid addition salt of a pharmaceutically acceptable free acid and a base compound, but is not limited thereto.
  • Preferred salt forms of the compounds according to the present invention include salts with inorganic acids or organic acids.
  • the inorganic acid may be hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, bromic acid, or the like.
  • organic acids include acetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, citric acid, gluconic acid, tartaric acid, salicylic acid, malic acid, Oxalic acid, benzoic acid, embonic acid, aspartic acid, glutamic acid and the like can be used.
  • Organic bases that can be used in preparing the organic base addition salt include tris(hydroxymethyl)methylamine and dicyclohexylamine.
  • Amino acids that can be used in preparing amino acid addition salts are natural amino acids such as alanine and glycine. It will be apparent to those skilled in the art that acids or bases other than the inorganic acids, organic acids, organic bases, and amino acids exemplified above may be used.
  • the salt may be prepared by a conventional method.
  • the compounds according to the present invention may have an asymmetric carbon center, they may exist as R or S isomers or racemic compounds, and all optical isomers and mixtures thereof may be included in the scope of the present invention.
  • prevention may include without limitation any action that blocks symptoms caused by age-related macular degeneration by using the pharmaceutical composition of the present invention, or suppresses or delays the symptoms.
  • treatment may include without limitation any action that improves or benefits symptoms caused by age-related macular degeneration by using the pharmaceutical composition of the present invention.
  • the pharmaceutical composition may be in the form of capsules, tablets, granules, injections, ointments, powders or beverages, preferably animals, more preferably mammals, and most preferably humans. It can be characterized as target.
  • administration means introducing the composition of the present invention to a patient by any suitable method, and the administration route of the composition of the present invention is through any general route as long as it can reach the target tissue.
  • oral administration intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, intranasal administration, intrapulmonary administration, intrarectal administration, intracavitary administration, intraperitoneal administration, intrathecal administration, or intraocular administration It may be made in the form, and the intraocular administration is more specifically intravitreal injection, retrobulbar injection, subconjunctival injection, sub-tenon injection, or It may be made in the form of intraocular drops, but is not limited thereto.
  • the effective amount is the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type of formulation and the patient's age, weight, general health condition, sex and diet, administration time, administration route And it can be adjusted according to various factors including the secretion rate of the composition, the treatment period, and drugs used simultaneously.
  • the therapeutic pharmaceutical composition can be administered to the body in an amount of 50 ml to 500 ml once, and in the case of a compound, 0.1 ng/kg-10 mg/kg, and in the case of a monoclonal antibody, 0.1 ng/kg-10 mg /kg may be administered.
  • the administration interval may be 1 to 12 times a day, and in the case of administration 12 times a day, it may be administered once every 2 hours.
  • the pharmaceutical composition of the present invention can be administered alone or with other treatments known in the art for the desired treatment, such as chemotherapy, radiation, and surgery.
  • the pharmaceutical composition of the present invention may be administered in combination with other therapies designed to enhance the immune response, such as adjuvants or cytokines (or nucleic acids encoding cytokines) well known in the art.
  • Other standard delivery methods may also be used, such as biolistic delivery or ex vivo treatment.
  • antigen presenting cells for example, antigen presenting cells (APCs), dendritic cells, peripheral blood mononuclear cells, or bone marrow cells may be obtained from a patient or a suitable donor, activated in vitro with the present pharmaceutical composition, and then administered to the patient. have.
  • APCs antigen presenting cells
  • dendritic cells dendritic cells
  • peripheral blood mononuclear cells or bone marrow cells
  • bone marrow cells may be obtained from a patient or a suitable donor, activated in vitro with the present pharmaceutical composition, and then administered to the patient. have.
  • "food composition” is used in various ways to prevent or improve the indications aimed at in the present invention
  • the food composition containing the composition of the present invention as an active ingredient is various foods, such as For example, it can be manufactured in the form of beverages, gum, tea, vitamin complexes, powders, granules, tablets, capsules, confectionery, rice cakes, and bread. Since the food composition of the present invention is improved from existing food intakes with little toxicity and side effects, it can be safely used even when taken for a long period of time for preventive purposes.
  • the amount may be added in an amount of 0.1 to 100% of the total weight.
  • natural carbohydrates include monosaccharides such as glucose, disaccharides such as fructose, polysaccharides such as sucrose, and common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. can do.
  • the flavoring agent examples include natural flavoring agents (thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.).
  • the food composition of is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, Stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc. These components may be used independently or in combination
  • the ratio of these additives is usually per 100 parts by weight of the composition of the present invention It is generally selected from the range of 0.1 to 100 parts by weight, but is not limited thereto.
  • a pharmaceutical composition for preventing or treating age-related macular degeneration comprising nicotinamide or a derivative thereof as an active ingredient, wherein the age-related macular degeneration is dry or wet, age-related macular degeneration
  • a pharmaceutical composition for prevention or treatment wherein the age-related macular degeneration is accompanied by drusen, pigmentary abnormality, or atrophy of the retinal epithelium. It provides, and the atrophy provides a pharmaceutical composition for preventing or treating age-related macular degeneration, which is a geographic atrophy.
  • the nicotinamide is represented by Formula 1 below, and the nicotinamide derivative is represented by Formula 2 or Formula 3 below.
  • a food composition for preventing or improving age-related macular degeneration comprising nicotinamide or a derivative thereof as an active ingredient, wherein the age-related macular degeneration is dry or wet
  • a food composition for prevention or improvement wherein the age-related macular degeneration is accompanied by drusen, pigmentary abnormality, or atrophy of the retinal epithelium.
  • a food composition for preventing or improving age-related macular degeneration It provides, and the atrophy provides a food composition for preventing or improving age-related macular degeneration, which is a geographic atrophy.
  • the nicotinamide is represented by Formula 1 below, and the nicotinamide derivative is represented by Formula 2 or Formula 3 below.
  • a pharmaceutical composition and a food composition containing nicotinamide or a derivative thereof according to the present invention as an active ingredient have an effect of significantly recovering structurally and functionally the degeneration of retinal epithelial cells in age-related macular degeneration.
  • FIG. 2 is a result of structurally confirming the treatment effect of age-related macular degeneration in retinal epithelial cells according to the candidate substance administered in an age-related macular degeneration animal model prepared using a lentivirus according to an embodiment of the present invention.
  • 3 is a result of structurally confirming the treatment effect of age-related macular degeneration in retinal epithelial cells according to the candidate substance administered to the age-related macular degeneration animal model prepared using sodium iodate according to an embodiment of the present invention.
  • 4a to 4d are the results of functionally confirming the treatment effect of age-related macular degeneration in retinal epithelial cells according to the candidate substance administered in the age-related macular degeneration animal model prepared using sodium iodate according to an embodiment of the present invention. .
  • An age-related macular degeneration animal model realizing geographic atrophy was prepared, and the compounds of Table 1 were administered as candidates for treatment of age-related macular degeneration.
  • the control group to which the compound was not administered showed geographic atrophy of typical age-related macular degeneration, but in the case of administration of the compound of Table 1, the order of Formula 2 (NMN) ⁇ Formula 3 (NR) > Formula 1 (NAM) It was confirmed that structural or functional recovery of retinal epithelial cell degeneration was remarkable.
  • Age-related macular degeneration animal model is the same as the previously known method (Kaneko, H. et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471, 325-330, doi:10.1038/nature09830. 2011.) performed.
  • This method is a method of generating geographic atrophy by Alu RNA accumulated in retinal pigment epithelium (RPE).
  • GFP green fluorescence protein
  • Alu RNA expressing lentival vector Alu RNA expressing lentival vector
  • WPI microliter syringe
  • GC 0.8 X 10 8 genome copy
  • a small incision is made with a 30 gauge injection needle at a location 1 mm away from the limbus, and a 33 gauge blunt needle of a microliter syringe is inserted through the incision, and a point where resistance is felt (subretinal space) ), the needle was approached.
  • antibiotic ointment was applied to the ocular surface.
  • the experiments were performed on a heating pad to maintain the body temperature of the mice. After 2 weeks, eye samples were obtained from the mice and RPE whole mount immunostatining was performed.
  • an animal model for age-related macular degeneration using a chemical method was additionally prepared.
  • 8-10 week-old C57BL/6 mice were prepared in the same manner as above, and sodium iodate (NAIO 3 ) was injected intravascularly through the tail vein at a concentration of 20 mg/Kg.
  • an electroretinogram (ERG) was performed, and eye samples were obtained from mice, and RPE whole mount immunostatining was performed.
  • Candidates for the treatment of age-related macular degeneration used the compounds in Table 1 below, and from 3 days before administration of lentivirus or sodium iodate for preparing the above two types of animal models to the day of obtaining eye samples, 1000 mg/Kg/ It was intraperitoneal injection every day at the concentration of day.
  • Example 2 Confirmation of age-related macular degeneration treatment effect of candidate substance through confirmation of retinal epithelial cell morphology
  • Retinal cell staining for confirmation of retinal epithelial cell morphology was performed in the following order.
  • the obtained eye sample was fixed with 1% paraformaldehyde for 1 hour, and after removing the muscle, cornea, lens, and neural retina, Sclera
  • the /Choroid/RPE complex was radially sectioned into eight pieces.
  • Each tissue section was prepared in Phosphate buffered saline containing 5% bovine serum albumin, 2% NDS (normal donkey serum), and 0.3% TritonTM X-100. -buffered saline) solution for 1 hour after blocking, washing, and overnight reaction with anti-ZO-1 antibody at 4°C (overnight incubation). Thereafter, the cells were washed three times, reacted with the secondary antibody at room temperature for 1 hour, washed again, and the tissues were smeared on slides and then embedded. This was observed with a fluorescence microscope.
  • Example 2-1 Confirmation of effect in animal models using lentivirus
  • FIG. 1 the result of confirming whether the age-related macular degeneration animal model prepared by the method using the lentivirus in Example 1 was prepared as intended is shown in FIG. 1.
  • Figure 1 when transduction of lentivirus expressing GFP as a control, no structural change occurred in normal retinal epithelial cells (left), but when transduction of lentivirus expressing Alu RNA, retinal epithelial cells degenerated As a result, the retinal epithelial cells increased in size and became irregular in shape (right). Through this, it was confirmed that the target age-related macular degeneration animal model was well prepared by the method using the lentivirus.
  • the control group (Alu RNA) to which the compound was not administered showed typical geographic atrophy of age-related macular degeneration.
  • Formula 1 was administered (Alu RNA + NAM treatment)
  • an increase in the size of retinal epithelial cells was observed, but the size of retinal epithelial cells was significantly smaller than that of the control group (Alu RNA).
  • Example 2-2 Confirmation of effect in animal models using sodium iodate
  • Example 3 Confirmation of age-related macular degeneration treatment effect of candidate substance through visual acuity measurement in objective view
  • the present invention relates to a pharmaceutical composition for preventing or treating age-related macular degeneration.
  • Age-related macular degeneration is a disease caused by various changes in the macular area of the retina with aging. The incidence increases with age, and it is known that there are about 200 million patients worldwide as the number one cause of adult blindness in developed countries. However, progressive macular degeneration, which accounts for most of AMD, is called geographic atrophy (GA), and currently there is no treatment, which is the biggest challenge in age-related macular degeneration.
  • GA geographic atrophy
  • the pharmaceutical composition of the present invention is expected to be widely used in the medical field because it exhibited a very remarkable therapeutic effect not only in wet but also in dry age-related macular degeneration for which there is no treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire liée à l'âge. La dégénérescence maculaire liée à l'âge est la cause numéro un de cécité chez les adultes dans les pays développés. La dégénérescence maculaire sèche liée à l'âge, qui est le type plus commun de dégénérescence maculaire liée à l'âge, est actuellement le problème le plus grave étant donné qu'il n'y a pas de traitement pour la maladie. La composition pharmaceutique et une composition alimentaire selon la présente invention comprenant du nicotinamide ou un dérivé de celui-ci en tant que principe actif ont un effet de soulagement significatif, structurellement et fonctionnellement, de la dégénérescence des cellules épithéliales rétiniennes dans la dégénérescence maculaire liée à l'âge. On s'attend donc à ce qu'elles soient largement utilisées dans le domaine médical.
PCT/KR2022/006706 2021-05-11 2022-05-11 Composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire liée à l'âge Ceased WO2022240165A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0060802 2021-05-11
KR1020210060802A KR102633321B1 (ko) 2021-05-11 2021-05-11 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물

Publications (1)

Publication Number Publication Date
WO2022240165A1 true WO2022240165A1 (fr) 2022-11-17

Family

ID=84028669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/006706 Ceased WO2022240165A1 (fr) 2021-05-11 2022-05-11 Composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire liée à l'âge

Country Status (2)

Country Link
KR (1) KR102633321B1 (fr)
WO (1) WO2022240165A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170058976A (ko) * 2014-09-17 2017-05-29 팬옵티카, 인크. 약물 전달 및 전안부 보호를 위한 안구용 제제
KR20170120583A (ko) * 2014-12-30 2017-10-31 셀 큐어 뉴로사이언시스 리미티드 망막 질환의 치료 방법
KR20180039658A (ko) * 2015-08-05 2018-04-18 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170058976A (ko) * 2014-09-17 2017-05-29 팬옵티카, 인크. 약물 전달 및 전안부 보호를 위한 안구용 제제
KR20170120583A (ko) * 2014-12-30 2017-10-31 셀 큐어 뉴로사이언시스 리미티드 망막 질환의 치료 방법
KR20180039658A (ko) * 2015-08-05 2018-04-18 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EBELING MARA C., POLANCO JORGE R., QU JUN, TU CHENGJIAN, MONTEZUMA SANDRA R., FERRINGTON DEBORAH A.: "Improving retinal mitochondrial function as a treatment for age-related macular degeneration", REDOX BIOLOGY, vol. 34, 1 July 2020 (2020-07-01), NL , pages 1 - 13, XP093004003, ISSN: 2213-2317, DOI: 10.1016/j.redox.2020.101552 *
SAINI JANMEET S.; CORNEO BARBARA; MILLER JUSTINE D.; KIEHL THOMAS R.; WANG QINGJIE; BOLES NATHAN C.; BLENKINSOP TIMOTHY A.; STERN : "Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration", CELL STEM CELL, vol. 20, no. 5, 4 May 2017 (2017-05-04), AMSTERDAM, NL , pages 1 - 20, XP085000091, ISSN: 1934-5909, DOI: 10.1016/j.stem.2016.12.015 *

Also Published As

Publication number Publication date
KR102633321B1 (ko) 2024-02-05
KR20220153343A (ko) 2022-11-18

Similar Documents

Publication Publication Date Title
TW201038544A (en) Anti-neurodegenerative diseases agents
US20110130388A1 (en) Prophylactic or therapeutic agent for axial myopia
JP6874075B2 (ja) 眼疾患を治療するためのタイワンプロポリス抽出物
TWI666324B (zh) 蟬花活性物質及其用於降低眼壓之用途
CN102218051A (zh) 丙戊酸钠在制备治疗或改善青光眼视神经病变的药物中的用途
WO2022240165A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire liée à l'âge
CN114869885A (zh) 和厚朴酚眼用药物的制备及其在真菌性角膜炎治疗中的应用
CN102258518A (zh) 石杉碱甲在制备治疗青光眼和/或缺血诱发的视神经损伤的药物中的用途
CN117338700B (zh) 功能水凝胶及其制备和在制备治疗青光眼药物中的应用
WO2025101045A1 (fr) Composition pharmaceutique pour le traitement ou la prévention de maladies oculaires contenant du broussochalcone a en tant que principe actif
KR20040014600A (ko) 알파1 수용체 차단약을 유효 성분으로 하는 시신경 보호제
KR20100124756A (ko) 시신경 장해를 동반하는 안질환의 예방 또는 치료제
WO2005072066A2 (fr) Agent pour la prevention ou le traitement de la maculopathie diabetique
US10967029B2 (en) Method of using Cistanche tubulosa extract to prevent, slow down, or treat an eye disease caused by oxidative stress
CN116115653B (zh) 猴头菇菌丝体活性物质用于制备预防或治疗视网膜病变的组合物的用途
WO2020091430A1 (fr) Composition de prévention ou de traitement de la dégénérescence maculaire
EP2072047A1 (fr) Agent thérapeutique pour maladie ophtalmique
WO2022255553A1 (fr) Composition pour la prévention ou le traitement de maladies oculaires comprenant des vésicules extracellulaires issues de lactobacillus paracasei
CN112999233A (zh) 一类来源于赤芍的单萜苷类化合物及其制法和应用
KR102880598B1 (ko) 식방풍 잎 추출물을 유효성분으로 함유하는 청색광 노출에 대한 시력 보호용 조성물
CN114601843A (zh) 淫羊藿苷在制备治疗自身免疫性葡萄膜炎药物中的用途
KR100653557B1 (ko) 카이로 이노시톨 또는 피니톨의 백내장 예방치료제로서의용도와 그 조성물
WO2025165207A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies neurologiques comprenant du dextrométhorphane en tant que principe actif
US20080318939A1 (en) Methods for treating ophthalmic disorders
WO2023033483A1 (fr) Composition pharmaceutique de prévention ou de traitement d'une maladie oculaire diabétique comprenant un inhibiteur de sglt-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22807812

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22807812

Country of ref document: EP

Kind code of ref document: A1